Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders

LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders

US Patent 9701627 · Granted Jul 11, 2017

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Inhibitors of extracellular signal-regulated kinase2025
WNT signaling pathway inhibitors for treatments of disease2025
Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors2025
Non-catalytic substrate-selective p38α-specific MAPK inhibitors with endothelial2024
Non-catalytic substrate-selective p38alpha-specific MAPK inhibitors with endothe2024
Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors2023
Car activator agents for cyclophosphamide-based treatments of cancer2023
WNT signaling pathway inhibitors for treatments of disease2023
RUNX2 transcription factor inhibitors and uses thereof2023
Protein translation inhibitors and uses thereof2022
Non-catalytic substrate-selective, p38α-specific MAPK inhibitors with endothelia2022
Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors2021